Kornimate/medical-research-clean huggingface dataset:
total marrow irradiation with high dose melphalan prior to autologous transplant for multiple myeloma

Conditions: Multiple Myeloma

Summary: in this phase i trial, patients with multiple myeloma will receive standard high dose melphalan with autologous stem cell rescue. in addition the pre-transplant conditioning will include targeted total marrow irradiation (tmi). this conventional 3+3 phase i trial will increase the dose of tmi until the maximum tolerated dose (mtd) is reached. initial patients enrolled will receive the lowest possible dose of 3gy. maximum dose will be 12gy.

to establish the maximal tolerated dose of total marrow irradiation which can be added to high dose melphalan conditioning in patients with multiple myeloma undergoing autologous stem cell transplant.

Eligibility criteria:
inclusion criteria: 1. patients meeting criteria for symptomatic myeloma 2. patients must be high or intermediate risk of disease progression as defined by having one of the following criteria: 2.1 iss stage 2 or 3 disease 2.2 abnormal metaphase cytogenetics 2.3 presence of fish abnormalities aside from hyperdiploidy 3. patients who have received at least 2 cycles of systemic treatment of any kind in the preceding 12 months 4. patient age 18-75 years at time of enrollment 5. karnofsky performance status of ≥70 6. cardiac function: lvef \>40% 7. hepatic: bilirubin \<2x upper limit of normal and alt and ast \< 2.5x the upper limit of normal 8. renal: creatinine clearance of ≥30ml/min, estimated or calculated 9. pulmonary: dlco, fev1, fvc \>50% of predicted (after correction for hemoglobin) exclusion criteria: 1. patients with diagnosis of plasma cell leukemia 2. patients with myeloma who have had any disease progression prior to enrollment 3. patients with truly non secretory myeloma (patients with light chain disease are eligible) 4. pregnant or breast-feeding 5. uncontrolled viral, fungal or bacterial infection note: infection is permitted if there is evidence of response to medication. eligibility of hiv infected patients will be determined on a case-by-case basis. 6. patients who have undergone prior allograft or autologous transplant 7. prior solid organ transplant 8. patients receiving prior radiation to more than 20% of bone marrow containing areas

Keywords: multiple myeloma high risk intermediate risk symptomatic
comprehensive assessment of risks for miscarriage.

Conditions: Spontaneous Abortion

Summary: this study aims to determine the role of serum biomarkers and placental bloodflow in the comprehensive evaluation of the risk for spontaneous abortion

to study the added value (if any) of combining serum markers, immunologic factors, and ultrasound parameters in comprehensively evaluating the risk for spontaneous abortion.

Eligibility criteria:
inclusion criteria: * visualized fetal structures in utero \& heart pulsations until 8th week of gestation * normal ths/t4 levels * no uterine malformations * bmi \< 27 * signed informed consent exclusion criteria: * fetal structures in utero \& heart pulsations not visualized until the 8th week of gestation * elevated ths/t4 levels * uterine malformations * bmi \> 27
expanded access program for maraviroc at multiple centers

Conditions: HIV Infections

Summary: to provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.


Eligibility criteria:
inclusion criteria: * subjects must be failing to achieve adequate virologic suppression on their current regimen and have hiv-1 rna greater than or equal to 1000 copies/ml, at screening * have only r5 hiv-1 at screening as verified by the monogram biosciences trofile assay * minimum age must be 16 years or minimum adult age as determined by local regulatory authorities or directed by local law. exclusion criteria: * failed prior treatment with any ccr5 antagonist, in any ongoing ccr5 trial or having previously prematurely discontinued maraviroc in trials

Keywords: hiv infections
personalized treatment for endometrial carcinoma

Conditions: Endometrial Adenocarcinoma

Summary: the goal of this clinical trial is to compare the efficacy of adjuvant therapies in women with stage i-ii molecular integrated high-intermediate or high-risk endometrial carcinoma. specifically, the invesigators want to compare: * chemotherapy vs. chemoradiotherapy in p53 abn subtype and nonendometrioid carcinomas. * vaginal brachytherapy vs. whole pelvic radiotherapy in the mmr-d molecular subgroup. * vaginal brachytherapy vs. whole pelvic radiotherapy in the nsmp molecular subgroup.

endometrial carcinomas can be classified into four molecular subgroups, i.e. mismatch repair deficient (mmr-d), p53 abnormal (p53 abn), polymerase-ϵ (pole) ultramutated, and "no specific molecular profile" (nsmp). molecular subgroups can be considered to be distinct diseases as they are associated with different clinicopathologic characteristics, prognoses and, possibly, responses to adjuvant therapy. molecular classification of endometrial carcinoma is recommended to be implemented in routine clinical practice to improve prognostication and triage to adjuvant therapy. the personalized treatment for endometrial carcinoma (petrec) trial, led by the finnish gynecologic oncology group (fingog), is a multicenter prospective clinical trial for women with stage i-ii molecular integrated high-intermediate or high-risk endometrial carcinoma. the efficacy of chemotherapy vs. chemoradiotherapy is compared in p53 abn subtype and nonendometrioid carcinomas, and vaginal brachytherapy vs. whole pelvic radiotherapy in mmr-d and nsmp molecular subgroups. patients who consent to follow-up within the trial but not to randomization are treated as recommended in multidisciplinary meetings and enrolled for follow-up only (comprehensive cohort study design). the primary outcome is the 5-year cumulative incidence of disease recurrence. secondary outcomes are vaginal, pelvic, and distant recurrence rates, 5-year recurrence-free and overall survival, adverse events, and patient-reported symptoms and quality of life. the findings of the trial may eventually help decrease under- and overtreatment and, consequently, improve patient outcome and decrease treatment-associated adverse effects.

Eligibility criteria:
inclusion criteria: * age 18 to 100 years * who performance status 0 to 2 * stage i-ii molecular integrated high-intermediate or high-risk endometrial carcinoma exclusion criteria: * age \ 100 years * who performance status \>2 * uterine sarcoma * a history of malignancy within 5 years * previous pelvic radiotherapy * an interval of \>30 days between surgery and start of chemotherapy or \>8 weeks between surgery and start of radiotherapy (longer intervals may be permitted with investigator´s approval)

Keywords: endometrial carcinoma molecular classification adjuvant therapy
z-plasty and heineke-mikulicz scrotoplasty in the management of penoscrotal web

Conditions: Urologic Diseases

Summary: the goal of this clinical trial is to compare the surgical outcome of z-scrotoplasty versus heineke-mikulicz scrotoplasty in the management of congenital penoscrotal web in pediatric age group. the main question\[s\] it aims to answer are: • question 1: is there a difference in the surgical outcome between using z-scrotoplasty and heinke miculickz scrotoplasty in the management of congenital penoscrotal web?\] participants will be divided into two groups; group a treated by z-scrotoplasty and group b treated by heineke miculickz scrotoplasty.

background: the penoscrotal web may be congenital or acquired after excessive removal of ventral skin during circumcision. there are several previously described surgical techniques for the treatment of congenital webbed penis without a clear comparison between their outcomes. purpose: the objective of our study was to compare the surgical results of z-scrotoplasty and heineke-mikulicz scrotoplasty in the treatment of congenital webbed penis. patients \& methods: our prospective study included 40 uncircumcised patients presented with a webbed penis. they were divided into group a which was treated by z-scrotoplasty and group b which was treated by heineke-mikulicz scrotoplasty.

Eligibility criteria:
inclusion criteria: * patients with congenital penoscrotal web in the pediatric age group exclusion criteria: * patients with any penile anomalies

Keywords: penoscrotal web z-scrotoplasty heineke-mikulicz
exercise in patients with advanced non-small cell lung cancer

Conditions: Advanced Lung Carcinoma; First Line Treatment; Second Line Treatment; NSCLC Stage IV; NSCLC Stage IIIB; Palliative Treatment; NSCLC Stage IIIC

Summary: lung cancer is one of the most common types of cancer in germany, with 56,839 new cases and 45,072 deaths annually. approximately 70% of patients with non-small cell lung cancer (nsclc) are diagnosed at an advanced stage and suffer from comorbidities and symptoms such as fatigue, tiredness, and loss of strength. the standard first-line treatment for metastatic nsclc includes platinum-based chemoimmunotherapy followed by immunotherapy maintenance. exercise can have positive effects on symptoms such as shortness of breath, fatigue, quality of life, and physical fitness. however, there is a lack of current scientific evidence for the effectiveness of exercise in advanced lung cancer patients. no current trial investigated exercise in advanced nsclc receiving immunotherapy so far. the breath-study is a prospective 3-arm randomized controlled trial (rct). in total, the investigators plan to recruit 104 patients. a 2:1:1 randomization will be performed with three study groups: a control group and two exercise therapy groups (strength+endurance exercise/only endurance exercise). one group receives individual endurance training and the other group a combination of individual endurance and strength training. both treatment groups will be treated twice a week for 12 weeks. the control group will initially receive standard treatment without exercise for 12 weeks and will then be randomized into one of the other two study groups with exercise twice a week for 12 weeks. this approach allows for a sufficiently large sample for comparisons between exercise therapy and the control group, as well as between the two exercise therapy approaches. the primary aim is to investigate the impact of exercise on v02peak. secondarily endpoints aim to investigate changes in physical function, patient related outcomes and cardiac function before and after exercise.


Eligibility criteria:
inclusion criteria * patients with histologically confirmed non-small cell lung carcinoma in uicc stages iiib and iv * first- or second-line therapy (inclusion up to 28 days after the first cycle) in palliative intention * age ≥ 18 years * signed informed consent exclusion criteria * severe cardiopulmonary disease (ef\<30%) * newly occurring or progressive uncontrolled cns (central nervous system) metastases * expected life expectancy \< 3 months * bone metastases with acute risk of fracture * ecog (eastern cooperative oncology group) performance status \> 2 * acute pulmonary embolism * acute myocardial infarction * requiring surgery for aortic aneurysm * tension pneumothorax * lack of proficiency in the german language * active infection
a study to assess the hematopoyetic response of anemic patients with hematologic malignancies treated with erythropoietin b

Conditions: Anemia

Summary: this study will examine the efficacy, safety and effect on hemoglobin levels, of once weekly subcutaneous injections of epoetin beta (30,000 iu) in anemic participants with non-hodgkin's lymphoma, chronic lymphocytic leukemia or multiple myeloma. the anticipated study duration is 4 months, and the target sample size is 30 individuals.


Eligibility criteria:
inclusion criteria: * adult participants with a diagnosis of non-hodgkin's lymphoma, chronic lymphocytic leukemia or multiple myeloma * anemia at screening visit exclusion criteria: * transfusion of red blood cells within 2 months of study drug * treatment-resistant hypertension * acute or chronic bleeding (requiring therapy) within 3 months of study drug
psychiatric multi-omics and neuroimaging project

Conditions: Mental Disorders; Healthy Control

Summary: this study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.

the study seeks to identify possible biological markers of schizophrenia and the effects of gene-environment interactions on brain structural and functional networks. so we can help doctors and scientific researchers better understand the neuropathological basis of schizophrenia.

Eligibility criteria:
inclusion criteria: * age: 13-35 years old(patients with healthy siblings can be extended to 14-35 years of age) * course of disease: \<24 months * priority is given to patients who have never taken medicine or duration of drug use \< 2 weeks * no nuclear magnetic contraindications. exclusion criteria: * family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence * have a major physical disease or infectious disease * history of coma and serious neurological disease 4.mri contraindications.

Keywords: schizophrenia major depressive disorder autism spectrum disorder bipolar disorder magnetic resonance imaging multi-omics
ellume.lab flu a+b test and itreat flu a+b flu test performance versus viral culture and reverse transcriptase polymerase chain reaction.

Conditions: Influenza

Summary: the primary purpose of this study is to validate the sensitivity and specificity of the itreat flu a+b test and the ellume.lab flu a+b test in detecting influenza a and influenza b as compared to viral culture. the secondary aims are to: validate the sensitivity and specificity of the itreat flu a+b test and the ellume.lab flu a+b test in detecting influenza a and influenza b as compared to reverse transcriptase polymerase chain reaction (rt-pcr). evaluate the correct interpretation of the itreat flu a+b test by subjects with influenza-like symptoms. evaluate the subjects' satisfaction with the convenience, comfort and ease of use of the itreat flu a+b test. evaluate the operators' satisfaction with the ease of use of the ellume.lab flu a+b test.


Eligibility criteria:
inclusion criteria: * male and female participants aged ≥ 18 years: itreat flu a+b test and ellume.lab flu a+b test or aged ≥ 1 and \<18 years: ellume.lab flu a+b test only; and * fever ≥ 37.8°c (100°f) at presentation or history or parent/guardian-reported history of fever ≥ 37.8°c (100°f) or feeling feverish within 24 hours of presentation; and * rhonorrhea or blocked nose; and * participant (or parent/legal guardian) capable and willing to give informed consent/assent; and * participant (or parent/legal guardian) able to read and write in english. exclusion criteria: * participants aged \<1 year. * participants who have undergone treatment with tamiflu (oseltamivir), relenza (zanamivir) or symmetral (amantadine) within the previous 7 days. * participants who have been vaccinated by means of an influenza nasal spray/mist vaccine within the previous 7 days. * participants who have had a nose bleed within the past 30 days. * participants who have had recent craniofacial injury or surgery, including surgery to correct deviation of the nasal septum, within the previous 6 months. * participants currently enrolled in another clinical trial or have used any investigational device within 30 days preceding informed consent. * participants 18 years of age or older unable to understand english and consent to participation. * parent/legal guardian of paticipants \<18 years of age unable to understand english and consent to participation of child. * participants who have had prior exposure to itreat flu a+b test. * participants who have been previously enrolled in the ie-flu-aus-1701 study.
a clinical trial for amn: validation of biomarkers of oxidative stress, efficacy and safety of a mixture of antioxidants

Conditions: Adrenomyeloneuropathy

Summary: x-linked adrenoleukodystrophy is a rare, demyelinating and neurodegenerative disorder, due to a loss of function of a fatty acid transporter, the peroxisomal abcd1protein. its more frequent phenotype, the adrenomyeloneuropathy in adults, is characterized by axonal degeneration in spinal cord, spastic paraparesis and a disabling peripheral neuropathy. actually, there is no efficient treatment for the disease. our work in the last twelve years dissecting the physiopathological basis of the disorder has uncovered an involvement of the oxidative stress early in the neurodegenerative cascade. in a preclinical trial we have identified an antioxidant cocktail that efficiently reverse the clinical symptoms and the axonal degeneration in the mouse model for the disease. we propose the translation of the results to an open trial to test the tolerance and effectiveness of these drugs in the correction of the previously identified oxidative lesion biomarkers, as a first step to a randomized versus placebo, multicentric and international trial. you will be clinically explored and assessed in the hospital universitari of bellvitge (hub) using clinical scales for spasticity, disability, electroneurogram and cranial and spinal nuclear magnetic resonance (nmr). the information will be collected in a data base that will be of great value to improve the present attention and the future follow-up to facilitate your inclusion in therapeutic randomized, double blind, against placebo clinical trials.


Eligibility criteria:
inclusion criteria: * symptomatic amn patients, * 18-64 years old, * male and female, * clinically and biochemically diagnosed; * females must be obligated heterozygotes or must have gene mutation identified. exclusion criteria: * pregnant and lactation in females, * cerebral inflammatory disease with cognitive disorder, and/or * need the help of two walking sticks, * epilepsy, * hypersensibility to cysteine related compounds, * transaminases 2 fold up normal values.

Keywords: xald amn
binaxnow covid-19 igg rapid test device and antibody self test

Conditions: COVID-19 Respiratory Infection

Summary: performance evaluation of the binaxnow™ covid-19 igg rapid test device (professional use) and with binaxnow™ covid-19 antibody self test wehn used with fingerstick capillary whole blood and plasma samples. the binaxnow™ antibody tests are lateral flow tests that measure sars-cov-2 igg antibodies.


Eligibility criteria:
inclusion criteria: 1. participant is 18 years of age or older. 2. evaluable individuals with a prior confirmed sars-cov-2 infection with prior covid-19 symptoms with symptoms onset \> 14 days prior to the study, or symptoms onset 8-14 days prior to the study, or symptoms onset 0-7 days prior to study.or evaluable individuals confirmed negative by sars-cov-2 rt-pcr using a sample obtained within 7 days prior to or on the day of the study. 3. participant agrees to complete all aspects of the study. exclusion criteria: 1. participant has already participated in this study on a previous occasion. 2. participant is enrolled in a study to evaluate a new drug. 3. participant has a visual impairment that cannot be restored using glasses or contact lenses. 4. participant is unable or unwilling to provide informed consent. 5. participant is a vulnerable person as deemed unfit for the study by the principal investigator. 6. participant has a condition deemed unfit to safely perform the test by the investigator. 7. participant is a practising health-care professional or laboratory scientist / technician.
effects of a health intervention on fear of hypoglycemia : a pilot study

Conditions: Type 2 Diabetes Mellitus; Fear of Hypoglycemia; Health Education; Impaired Awareness of Hypoglycemia; Self-Management

Summary: the purpose of this study was to construct a fear of hypoglycemia(foh) intervention program for type 2 diabetic patients based on the behaviour change wheel (bcw) theory and to investigate the feasibility, acceptability, and initial effects of the program.

in this study, eligible participants were randomized in a 1:1 ratio into an intervention group (health education based on bcw theory given on top of regular diabetes health education) and a control group (regular diabetes health education), with a 4-week intervention period and a 4-week follow-up period, for a total of 8 weeks.

Eligibility criteria:
inclusion criteria: * comply with the 2020 chinese guidelines for the prevention and treatment of type 2 diabetes mellitus * age ≥18 years * duration of diabetes mellitus ≥1 year * foh according to the elevated item endorsement criterion (e i criterion): ≥3 points on any item of the hypoglycemic fear-worry scale (hfs-ws) * patients who have the ability to listen, read, write, walk, and cooperate to complete the study * patients who have a smart phone, and can skillfully use wechat or telephone to communicate * voluntarily participate in this study and sign the informed consent form. exclusion criteria: * patients with comorbid acute complications or other serious diseases or disorders of consciousness, such as diabetic hypertonic state, tumors, coma, etc. * patients with comorbid psychiatric diseases or taking psychotropic drugs * patients who have recently or are participating in other studies on similar topics

Keywords: type 2 diabetes mellitus fear of hypoglycemia behavior change wheel theory impaired awareness of hypoglycemia self-management
remineralization efficacy of gum arabic varnish.

Conditions: Caries,Dental; Remineralization; White Spot Lesion

Summary: the aim of this study is to evaluate the remineralizing capacity of gum arabic varnish and its implementation into clinical practice.


Eligibility criteria:
inclusion criteria: * patients with initial carious lesions. * proper oral hygiene. exclusion criteria: * patients with a compromised medical history. * patients with active severe periodontal disease. * patients with hypoplastic or hypomineralized teeth.

Keywords: initial carious lesion gum arabic remineralization power fluoride varnish mi varnish acacia senegal
the prognostic and predictive value of the ca-125 marker in lung cancer monitoring

Conditions: Lung Cancer

Summary: the tumor associated ca-125antigen for diagnosis and follow-up of ovarian cancer was well defined. increased serum ca125 level may have many diagnoses other than ovarian cancer, including breast, colorectal and lung cancer. 80% lung cancer patients were diagnosed at advanced stage. malignant pleural effusion secondary to lung cancer represented the condition of cancer cell involved pleura. the ca-125 level may reflect the extent of tumor involved in pleura (tumor burden), it could be correlated with the prognosis. this study was performed to examine the properties of ca-125 by measuring pleural and blood ca-125 levels in lung cancer with or without malignant pleural effusion; meanwhile to examine whether the rate of decline in ca 125 during primary therapy as a surrogate indicator for survival.


Eligibility criteria:
inclusion criteria: * histologically proved lung cancer exclusion criteria: * history of other cancers within the past 5 years * pregnancy or breast milk feeding * tb pleuritis and peritonitis